Tammy Minshall
Family · Lees Summit, MONPI 1851821987
Payments from drug & device makers
Across 330 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$476
- AstraZeneca$448
- Pfizer$386
- Otsuka America Pharmaceutical, Inc.$299
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$247
- plus $3K from 40 others
What the payments were for
- Food & beverage$5,576100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$105
How this compares
$5,576 in reported general payments places this provider in the 90th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 27 | $32,120 |
| RexultiBrexpiprazole | 20 | $29,210 |
| OzempicSemaglutide | 15 | $23,634 |
| MounjaroTirzepatide | 18 | $22,514 |
| JardianceEmpagliflozin | 21 | $20,318 |
| FarxigaDapagliflozin Propanediol | 19 | $18,310 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,057 |
| EliquisApixaban | 21 | $12,340 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 13 | $9,016 |
| Lidocaine | 14 | $3,341 |
| Gabapentin | 84 | $1,638 |
| Trazodone Hcl | 52 | $1,236 |
| Hydroxyzine Hcl | 47 | $1,133 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 58 | $969 |
| MethotrexateMethotrexate Sodium | 15 | $913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $476 | $54,63445 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $299 | $29,21020 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $448 | $27,32532 claims |
| Novo NordiskOzempic | $49 | $23,63415 claims |
| Boehringer IngelheimJardiance | $149 | $20,31821 claims |
| GSKTrelegy Ellipta | $113 | $13,05720 claims |
| PfizerEliquis | $386 | $12,34021 claims |
| Almatica Pharma LLCSertraline Hcl | $18 | $26833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,812 family providers in Missouri.
Other family in Lees Summit
- Tamera WolfLees Summit$215K
- Crystal DavisonLees Summit$16K
- Christine HuntLees Summit$12K
- Connie SpencerSaint Joseph$320K
- Shayla SandersKansas City$306K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.